Vaccinations, cardiovascular drugs, hospitalisation and mortality in COVID-19 and Long COVID.
View/ Open
Pagination
107155 - ?
DOI
10.1016/j.ijid.2024.107155
Journal
Int J Infect Dis
Metadata
Show full item recordAbstract
OBJECTIVE: To identify highest-risk subgroups for COVID-19 and Long COVID(LC), particularly in contexts of influenza and cardiovascular disease(CVD). METHODS: Using national, linked electronic health records for England(NHS England Secure Data Environment via CVD-COVID-UK/COVID-IMPACT Consortium), we studied individuals(of all ages) with COVID-19 and LC (2020-2023). We compared all-cause hospitalisation and mortality by prior CVD, high CV risk, vaccination status(COVID-19/influenza), and CVD drugs, investigating impact of vaccination and CVD prevention using population preventable fractions. RESULTS: Hospitalisation and mortality were 15.3% and 2.0% among 17,373,850 individuals with COVID-19(LC rate 1.3%), and 16.8% and 1.4% among 301,115 with LC. Adjusted risk of mortality and hospitalisation were reduced with COVID-19 vaccination≥2 doses(COVID-19:HR 0.36 and 0.69; LC:0.44 and 0.90). With influenza vaccination, mortality was reduced, but not hospitalisation(COVID-19:0.86 and 1.01, and LC:0.72 and 1.05). Mortality and hospitalisation were reduced by CVD prevention in those with CVD, e.g. anticoagulants- COVID:19:0.69 and 0.92; LC:0.59 and 0.88; lipid lowering- COVID-19:0.69 and 0.86; LC:0.68 and 0.90. COVID-19 vaccination averted 245044 of 321383 and 7586 of 8738 preventable deaths after COVID-19 and LC, respectively. INTERPRETATION: Prior CVD and high CV risk are associated with increased hospitalisation and mortality in COVID-19 and LC. Targeted COVID-19 vaccination and CVD prevention are priority interventions. FUNDING: NIHR. HDR UK.
Authors
Dashtban, A; Mizani, M; Pasea, L; Tomlinson, C; Mu, Y; Islam, N; Rafferty, S; Warren-Gash, PC; Denaxas, PS; Horstmanshof, KCollections
- NIHR Advanced Imaging [387]
Language
Licence information
Copyright statements
Related items
Showing items related by title, author, creator and subject.
-
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Angus, DC; Derde, L; Al-Beidh, F; Annane, D; Arabi, Y; Beane, A; van Bentum-Puijk, W; Berry, L; Bhimani, Z; Bonten, M (2020-10-06)Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, ... -
Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia.
Taylor, RR; Trivedi, B; Patel, N; Singh, R; Ricketts, WM; Elliott, K; Yarwood, M; White, V; Hylton, H; Allen, R (Royal College of Physicians, 2021-06-08)BACKGROUND: The COVID-19 pandemic has strained healthcare systems and how best to address post-COVID health needs is uncertain. Here we describe the post-COVID symptoms of 675 patients followed up using a virtual review ... -
The Born in Bradford COVID-19 Research Study: Protocol for an adaptive mixed methods research study to gather actionable intelligence on the impact of COVID-19 on health inequalities amongst families living in Bradford.
McEachan, RRC; Dickerson, J; Bridges, S; Bryant, M; Cartwright, C; Islam, S; Lockyer, B; Rahman, A; Sheard, L; West, J (2020-08-13)The UK COVID-19 lockdown has included restricting social movement and interaction to slow the spread of disease and reduce demand on NHS acute services. It is likely that the impacts of restrictions will hit the least ...